SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to heightened community interest in its role as a core memory supplier within the AI infrastructure sector, with investors closely watching supply shortages and multi-year supply agreements. The stock is seeing significant volatility as market participants debate whether these memory cycles represent a permanent shift in valuation or a peaking trend ripe for correction.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as traders debate the potential supply chain impact of a massive labor strike at Samsung, with many viewing the disruption as a bullish catalyst for Micron to capture greater market share in the critical HBM sector. Community discussions are heavily focused on the stock's significant recent rally and its potential to re-rate as institutional investors navigate heightened market volatility and options expiration.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust (QQQ) is seeing intense volatility driven by speculation surrounding the Trump-Xi summit, with market participants closely monitoring potential trade deal outcomes and the impact of the ongoing AI hardware rally. The community is heavily focused on the "buy-the-dip" phenomenon, with traders debating whether persistent market resilience is a sign of long-term strength or a speculative bubble ready to burst.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending following a strong quarterly earnings report featuring revenue growth that beat analyst expectations and raised full-year guidance, fueled by accelerating enterprise adoption of its AI-powered features. Community sentiment is heavily focused on a potential short squeeze, with investors highlighting significant short interest and arguing that the companys strong net dollar retention and essential role in design workflows prove its long-term value despite broader market concerns about AI competition.

Robo.ai, Inc. engages in the design and development of smart electric vehicles. It aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology. The company was founded in 2016 and is headquartered in Dubai, United Arab Emirates.

Robo.ai Inc. - Ordinary Shares - Class B

Robo.ai Inc.

Robo.ai Inc. ($AIIO) is experiencing massive volatility and high-volume interest driven by intense speculation around a potential short squeeze, with community members closely tracking the stock's low float and extremely high cost-to-borrow rates. While retail traders are actively debating its potential for double-digit gains based on momentum and recent tech-related narratives, caution remains high regarding the sustainability of the price action and risks of rapid reversals.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

Boost Run Inc. is drawing significant community interest following its recent de-SPAC transition and a strategic partnership announcement with CDW that highlights its role as a key NVIDIA-certified infrastructure provider. Investors are actively discussing the stock's potential for a gamma squeeze, driven by a relatively tight float and favorable comparisons to other established players in the AI data center and cloud sector.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is generating significant investor buzz as the market anticipates the upcoming IPO of its data center partner, Cerebras, alongside the company's own earnings report. Community discussion is heavily focused on the stock's long-term potential as an AI infrastructure play, with many investors debating the impact of ongoing ATM offerings and short-term volatility versus the company's multi-year contract outlook.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are actively debating whether semiconductor stocks have reached a speculative breaking point, with some using SOXS to hedge against an anticipated AI sector correction and others warning about the dangers of volatility decay in leveraged ETFs. The community remains deeply divided, balancing high-conviction bear bets against the persistent strength of chipmakers fueled by massive capital expenditure and ongoing AI infrastructure growth.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened volatility as traders weigh the impact of recent high-profile partnerships against broader concerns over chip sector rotation and geopolitical tensions. While some investors are bullish on the company's long-term foundry expansion and its role as a key compute partner, others are raising alarms about potential overvaluation after a parabolic rally and the risks associated with sector-wide profit-taking.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to a significant earnings beat and raised full-year revenue guidance, sparking intense debate over whether the stock's growth potential justifies its complex capital structure. The community is actively weighing the company's surging backlog and defense partnerships against persistent concerns regarding dilution and the influence of market makers on share price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View

Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.

SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback

Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.

HC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock Price

HC Wainwright reduced their price target on Summit Therapeutics from $30.00 to $23.00 and set a "buy" rating for the company in a report on Monday...

Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by...

Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen

Wall Street Zen upgraded shares of Summit Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday...

<ul class="summary-bullets"><li>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.</li><li>Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.</li><li>The company’s interim update from its HARMONi-3 trial disappointed investors.&nbsp; Final data from the cohort remain on track for the second half of 2026.</li></ul> Shares of Summit Therapeutics Inc. (SMMT) closed 25% lower on Friday after the company reported a wider loss for the first quarter and an interim analysis update from its HARMONi-3 trial, prompting Piper Sandler to lower its price target on the stock.Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.<h2 class="st-heading-2">Summit’s Q1 Earnings</h2>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier, as the company ramps up spending on its lead asset ivonescimab in the treatment of non-small cell lung cancer (NSCLC).The company is studying Ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC in its HARMONi-3 trial, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors.In squamous tumors, an independent Data Monitoring Committee completed a pre-specified interim progression-free survival analysis in Q2 2026 and recommended that the study continue as planned with no safety concerns, the company said. However, it did not hit the high statistical bar for early success/stop. Final data from the cohort remain on track for the second half of 2026.In the non-squamous tumors cohort, enrollment is expected to be completed by the end of Q2 2026, and data readout is targeted for the first half of 2027.According to Piper Sandler, investors are now questioning whether the impressive effect size seen in Akeso's HARMONi-6 can be replicated in Summit's global HARMONi-3.HARMONi-6 is a trial conducted in China and sponsored by Akeso, which evaluates ivonescimab in combination with platinum-based chemotherapy compared with the drug tislelizumab and platinum-based chemotherapy in non-small cell lung cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SMMT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the selloff as an overreaction.<stembedurl>https://www.stocktwits.com/northern18738901/message/652058452</stembedurl>Another echoed the sentiment, expressing optimism for the stock to rally back up over $18 in two weeks.<stembedurl>https://www.stocktwits.com/BobBijawklah/message/652053579</stembedurl><a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> has fallen 35% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update

Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.

Equity

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - What's Next...

Summit Therapeutics Stock Dips After Q1 Financial Report

Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first quarter financial results. Here's what you should know.read more...

Futures Rise, Oil Slides On Iran Ceasefire Optimism After Best Month For Stocks Since 2020

Futures Rise, Oil Slides On Iran Ceasefire Optimism After Best Month For Stocks Since 2020 US equity futures are higher, set for a new all time high, as the rally that's pushed Wall Street to record...

Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its holdings in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 13.7% during the 4th quarter, according to its most recent disclosure with the SEC...

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest SMMT News

SMMTSummit Therapeutics Inc